Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 955 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Bayer Clear all
Completed Phase 2 Interventional Results available

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

NCT03439891
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions
Nivolumab, Sorafenib
Biological · Drug
Lead sponsor
Robin Kate Kelley
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

NCT04531813
View directory record Official record
Conditions
Hypersensitivity
Interventions
Butenafine HCl 1% (BAY1896425), Positive Control-Sodium lauryl sulfate (SLS), Negative Control
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes

NCT02869113
View directory record Official record
Conditions
Sunscreen Agents
Interventions
BAY98751 (Y65-110), BAY 98751 (Y65-102), BAY 98751 (Y65-106), Standard shampoo mixture (Control)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 4 Interventional

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

NCT04288323
View directory record Official record
Conditions
Liver Cancer, Liver Cirrhoses, Liver Carcinoma
Interventions
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 17 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 3 Interventional

Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

NCT00332020
View directory record Official record
Conditions
Prevention, Venous Thromboembolism
Interventions
Rivaroxaban (BAY59-7939), Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
2,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Denver, Colorado • Bay Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 1, 2026, 9:55 AM EDT
Terminated Phase 1 Interventional

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

NCT00543335
View directory record Official record
Conditions
Lung Cancer
Interventions
Sorafenib, Radiation Therapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 1, 2026, 9:55 AM EDT
Completed No phase listed Observational

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

NCT03359876
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 1, 2026, 9:55 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

NCT07625215
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
BAY 3670549, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

NCT02824042
View directory record Official record
Conditions
Medical Oncology
Interventions
Anetumab ravtansine (BAY94-9343), Itraconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Santa Monica, California • Detroit, Michigan • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Results available

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

NCT00420342
View directory record Official record
Conditions
Postmenopause, Hypertension, Pre-Hypertension
Interventions
Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 1, 2026, 9:55 AM EDT
Terminated Phase 1 Interventional

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

NCT04999202
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2416964, Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Altamonte Springs, Florida • Sarasota, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

NCT00320775
View directory record Official record
Conditions
Macular Degeneration
Interventions
VEGF Trap
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 1, 2026, 9:55 AM EDT
Terminated Phase 1 Interventional

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

NCT02138812
View directory record Official record
Conditions
Medical Oncology
Interventions
BAY1161909, Paclitaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Santa Monica, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

NCT00111007
View directory record Official record
Conditions
Melanoma
Interventions
Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sun Protection Factor Assay (SPF Assay 19008)

NCT02815202
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987517
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 1, 2026, 9:55 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

NCT00522301
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

NCT00509795
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Sep 1, 2026, 9:55 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

New Assessment System in Measuring Symptom Distress in Cancer Patients

NCT00505245
View directory record Official record
Conditions
Caregiver, Health Care Provider, Malignant Neoplasm, Physician
Interventions
Interview, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Recruiting No phase listed Observational

A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide

NCT07672119
View directory record Official record
Conditions
Prostate Cancer
Interventions
No intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
55 Years and older · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

NCT00924807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate, Bicalutamide, Sorafenib
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

NCT01049022
View directory record Official record
Conditions
Infections
Interventions
Moxifloxacin (Avelox, BAY12-8039)
Drug
Lead sponsor
Bayer
Industry
Eligibility
3 Months to 14 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 1, 2026, 9:55 AM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 2 Interventional

Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

NCT00086775
View directory record Official record
Conditions
Leukemia
Interventions
alemtuzumab, rituximab, fludarabine phosphate
Biological · Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
5
States / cities
Boston, Massachusetts • Jackson, Mississippi • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 1, 2026, 9:55 AM EDT